Le Lézard
Classified in: Health
Subjects: SVY, TDS, FVT

PureCircle Stevia Institute Debuts at the International Congress of Nutrition


Formerly Global Stevia Institute, PCSI Expands to Include Years of Extensive Research in Agriculture and Taste

BUENOS AIRES, Argentina, Oct. 16, 2017 /CNW/ -- PureCircle Stevia InstituteSM (PCSI) debuted today at the International Union of Nutritional Sciences (IUNS) 21st International Congress of Nutrition (ICN) taking place from October 15 ? 20 in Buenos Aires. PCSI, founded as the Global Stevia Institute in 2010, has an expanded mission to advance research and share leading, balanced, science-based information on the benefits of stevia related to nutrition and health in addition to two new core areas of research: ingredient & taste and agriculture.

The Institute will continue to be governed by an international advisory board of highly-respected experts, leading scientists and practitioners, and will focus on both education and research. PCSI is supported by PureCircle Ltd, the leading global innovator and supplier of stevia sweeteners.

At ICN, PureCircle Stevia Institute will have three research presentations in collaboration with other partners representing its research pillars.

Tuesday, October 17 9:00 ? 10:00 AM 
Consumer awareness and perception of sweeteners influences food and beverage decisions

The presentation will discuss recent consumer survey data from multiple countries (e.g. US, UK, Germany, Brazil, etc.) on the awareness of various sweeteners and sentiment about stevia. Results reveal varying levels of consumer awareness across regions.  Awareness consistently increases following regulatory approvals and launches of products. Of those consumers who are aware of stevia, majority view the ingredient positively, and generally more positively than both artificial sweeteners tested across all countries.

Tuesday, October 17 3:00 ? 4:30 PM
Advantages of sugar reduction with blends versus individual steviol glycosides

Stevia leaves contain over 40 steviol glycosides (SGs) which provide different sweetness and organoleptic properties. Rebaudioside A (Reb A) is one of the most abundant and has been the primary focus of stevia usage to date, but has some taste challenges. This presentation will speak to new sensory research that demonstrates that proprietary custom blends of stevia have a significantly better taste profile, are closer to that of sugar and are the preferred taste profile versus Reb A alone.

Thursday, October 19 12:30 ? 1:30 PM
Insights from the sequencing and annotation of the Stevia rebaudiana genome and their application in agronomy and health.

The presentation is about a breakthrough research achievement on the genome sequencing of three stevia cultivars.

"These recent advances in research clearly demonstrate that stevia is positively viewed by consumers and, these new stevia innovations can make a meaningful contribution to reducing calories in foods and beverages without sacrificing taste. In addition, the possibilities with the sequencing of the genome are enormous," said Priscilla Samuel, PhD, Director of the PureCircle Stevia Institute.  "We look forward to continuing to advance the science of stevia and educating all the various stakeholder communities globally, about the benefits of stevia."

 

SOURCE PureCircle Stevia Institute


These press releases may also interest you

at 10:10
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical...

at 10:10
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation...

at 10:07
The American Association of Critical-Care Nurses (AACN) has published "AACN Standards for Appropriate Staffing in Adult Critical Care," the specialty's first, action-oriented staffing standards. Appropriate staffing has long been one of the "AACN...

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...

at 10:05
Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I...

at 10:05
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held...



News published on and distributed by: